290 related articles for article (PubMed ID: 9377621)
21. A review of current clinical findings with fluvastatin.
Garnett WR
Am J Cardiol; 1996 Sep; 78(6A):20-5. PubMed ID: 8875971
[TBL] [Abstract][Full Text] [Related]
22. Fluvastatin versus pravastatin.
Chilton R
Am J Cardiol; 1996 Jul; 78(1):127. PubMed ID: 8712106
[No Abstract] [Full Text] [Related]
23. A model to assess the cost effectiveness of statins in achieving the UK National Service Framework target cholesterol levels.
Wilson K; Marriott J; Fuller S; Lacey L; Gillen D
Pharmacoeconomics; 2003; 21 Suppl 1():1-11. PubMed ID: 12648030
[TBL] [Abstract][Full Text] [Related]
24. Treatment of primary hypercholesterolaemia. Short-term efficacy and safety of increasing doses of simvastatin and pravastatin: a double-blind comparative study.
Stalenhoef AF; Lansberg PJ; Kroon AA; Kortmann B; De Haan AF; Stuyt PM; Kastelein JJ
J Intern Med; 1993 Jul; 234(1):77-82. PubMed ID: 8326293
[TBL] [Abstract][Full Text] [Related]
25. Comparative efficacy and tolerability of low-dose pravastatin versus lovastatin in patients with hypercholesterolemia.
Strauss WE; Lapsley D; Gaziano JM
Am Heart J; 1999 Mar; 137(3):458-62. PubMed ID: 10047626
[TBL] [Abstract][Full Text] [Related]
26. Managing dyslipidemia in the high-risk patient.
Stein EA
Am J Cardiol; 2002 Mar; 89(5A):50C-57C. PubMed ID: 11900720
[TBL] [Abstract][Full Text] [Related]
27. The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients. A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin.
Koren MJ; Smith DG; Hunninghake DB; Davidson MH; McKenney JM; Weiss SR; Schrott HG; Henley RW; Tresh P; McLain RW; Bakker-Arkema RG; Black DM
Pharmacoeconomics; 1998 Jul; 14(1):59-70. PubMed ID: 10182195
[TBL] [Abstract][Full Text] [Related]
28. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors.
Garnett WR
Am J Health Syst Pharm; 1995 Aug; 52(15):1639-45. PubMed ID: 7583826
[TBL] [Abstract][Full Text] [Related]
29. [Fluvastatin in the treatment of hyperlipoproteinemia, initial experience].
Ceska R
Vnitr Lek; 1996 Aug; 42(8):533-6. PubMed ID: 8967021
[TBL] [Abstract][Full Text] [Related]
30. Simvastatin. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia.
Plosker GL; McTavish D
Drugs; 1995 Aug; 50(2):334-63. PubMed ID: 8521762
[TBL] [Abstract][Full Text] [Related]
31. Fluvastatin in primary hypercholesterolemia: efficacy and safety in patients at high risk. An analysis of a clinical trial database.
Peters TK; Muratti EN; Mehra M
Am J Med; 1994 Jun; 96(6A):79S-83S. PubMed ID: 8017471
[TBL] [Abstract][Full Text] [Related]
32. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs.
Davis HR; Pula KK; Alton KB; Burrier RE; Watkins RW
Metabolism; 2001 Oct; 50(10):1234-41. PubMed ID: 11586500
[TBL] [Abstract][Full Text] [Related]
33. Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia.
Plosker GL; Wagstaff AJ
Drugs; 1996 Mar; 51(3):433-59. PubMed ID: 8882381
[TBL] [Abstract][Full Text] [Related]
34. Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders.
Murdock DK; Murdock AK; Murdock RW; Olson KJ; Frane AM; Kersten ME; Joyce DM; Gantner SE
Am Heart J; 1999 Jul; 138(1 Pt 1):151-5. PubMed ID: 10385779
[TBL] [Abstract][Full Text] [Related]
35. Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine.
Holdaas H; Hartmann A; Stenstrøm J; Dahl KJ; Borge M; Pfister P
Am J Cardiol; 1995 Jul; 76(2):102A-106A. PubMed ID: 7604781
[TBL] [Abstract][Full Text] [Related]
36. Changes in plasma apolipoprotein B-containing lipoparticle levels following therapy with fluvastatin and cholestyramine. European Fluvastatin Study Group.
Bard JM; Ose L; Hagen E; Duriez P; Pfister P; Fruchart JC; Dallongeville J
Am J Cardiol; 1995 Jul; 76(2):65A-70A. PubMed ID: 7604802
[TBL] [Abstract][Full Text] [Related]
37. Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia.
Broyles FE; Walden CE; Hunninghake DB; Hill-Williams D; Knopp RH
Am J Cardiol; 1995 Jul; 76(2):129A-135A. PubMed ID: 7604788
[TBL] [Abstract][Full Text] [Related]
38. Fluvastatin in severe hypercholesterolemia: analysis of a clinical trial database.
Peters TK
Am J Cardiol; 1995 Jul; 76(2):71A-75A. PubMed ID: 7604803
[TBL] [Abstract][Full Text] [Related]
39. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
[TBL] [Abstract][Full Text] [Related]
40. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
